Na YANG, Hua-bing ZHANG, Yu-xiu LI. Interpretation on the Update of American Diabetes Association Standards of Medical Care in Diabetes—2019[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 476-480. doi: 10.3969/j.issn.1674-9081.2019.05.009
Citation: Na YANG, Hua-bing ZHANG, Yu-xiu LI. Interpretation on the Update of American Diabetes Association Standards of Medical Care in Diabetes—2019[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 476-480. doi: 10.3969/j.issn.1674-9081.2019.05.009

Interpretation on the Update of American Diabetes Association Standards of Medical Care in Diabetes—2019

doi: 10.3969/j.issn.1674-9081.2019.05.009
More Information
  • Corresponding author: ZHANG Hua-bing Tel: 86-10-69155073, E-mail:huabingzhang@sina.com
  • Received Date: 2019-01-08
  • Publish Date: 2019-09-30
  • Diabetes mellitus is one of the most common chronic non-infectious diseases. The American Diabetes Association publishes a new version of Diabetes Medical Standards every year that provides guidance for clinicians in the prevention, diagnosis, and treatment of diabetes. The latest version was released in December 2018. This article interprets some of the updated contents in this edition of the Standards for reference, including Diabetic medications especially for patients with arteriosclerosis cardiovascular disease, chronic kidney disease, or heart failure, choices of injectable hypoglycemic agents, goals of blood pressure control, and the use of aspirin.
  • loading
  • [1] American Diabetes Association. American Diabetes Associa-tion Standards of Medical Care in Diabetes-2019[J]. Diabetes Care, 2019, 42:S1-S186. doi:  10.2337/dc19-Sint01
    [2] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志, 2018, 10:4-67.
    [3] Davies MJ, D'Alessio DA, Fradkin J, et al.Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care, 2018, 41:2669-2701. doi:  10.2337/dci18-0033
    [4] Jorsal A, Kistorp C, Holmager P, et al. Effect of lirag-lutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial[J]. Eur J Heart Fail, 2017, 19:69-77. doi:  10.1002/ejhf.657
    [5] Margulies KB, Hernandez AF, Redfield MM, et al.Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction:A Randomized Clinical Trial[J]. JAMA, 2016, 316:500-508. doi:  10.1001/jama.2016.10260
    [6] Marso SP, Bain SC, Consoli A, et al.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375:1834-1844. doi:  10.1056/NEJMoa1607141
    [7] Marso SP, Daniels GH, Brown-Frandsen K, et al.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2016, 375:311-322. doi:  10.1056/NEJMoa1603827
    [8] Neal B, Perkovic V, Mahaffey KW, et al.Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes[J]. N Engl J Med, 2017, 377:644-657. doi:  10.1056/NEJMoa1611925
    [9] Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)[J]. Cardiovasc Diabetol, 2014, 13:102. doi:  10.1186/1475-2840-13-102
    [10] Abd El Aziz MS, Kahle M, Meier JJ, et al.A meta-analysis comparing clinical effects of short-or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients[J]. Diabetes Obes Metab, 2017, 19:216-227. doi:  10.1111/dom.12804
    [11] Bowman L, Mafham M, Wallendszus K, et al.Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus[J]. N Engl J Med, 2018, 379:1529-1539. doi:  10.1056/NEJMoa1804988
    [12] Gaziano JM, Brotons C, Coppolecchia R, et al.Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE):a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2018, 392:1036-1046. doi:  10.1016/S0140-6736(18)31924-X
    [13] Group ASC, Bowman L, Mafham M, et al.Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus[J]. N Engl J Med, 2018, 379:1529-1539. doi:  10.1056/NEJMoa1804988
    [14] 朱铁楠.抗血小板治疗实验室监测之我见[J].协和医学杂志, 2018, 9:123-126. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201802006
    [15] Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose:analysis of individual patient data from randomised trials[J]. Lancet, 2018, 392:387-399. doi:  10.1016/S0140-6736(18)31133-4
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (370) PDF downloads(1605) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return